Dose-response effect of somatostatin-14 on human basal pancreatic hormones

Pancreas. 1987;2(5):551-6. doi: 10.1097/00006676-198709000-00010.

Abstract

The effect of increased doses of Somatostatin-14 (3, 10, 30, 100, 300 micrograms/h) on basal release of insulin, pancreatic glucagon and pancreatic polypeptide (PP) was investigated on eight normal volunteers. Levels of Somatostatin-like immunoreactivity (SLI) was determined in order to correlate the increased SLI levels with the degree of islet hormone inhibition (r = 0.9947, p less than 0.01). By increasing the basal levels of SLI by one-third, a significant inhibition (p less than 0.01) of insulin, glucagon, and PP was noted (78.5, 78.6, 75.2%, respectively, on basal levels). The maximal effect was obtained with 300 micrograms/h for insulin, with 30 micrograms/h for glucagon and 100 micrograms/h for PP. In evaluating the relative inhibitory potency of somatostatin, expressed as ED50, the theoretic potency of somatostatin on each peptide had similar values, ranging from 30 to 10 micrograms/h. The present data show that a minimal peripheric increase in SLI is able to regulate basal islet pancreatic hormones.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Depression, Chemical
  • Dose-Response Relationship, Drug
  • Female
  • Glucagon / blood
  • Humans
  • Infusion Pumps
  • Insulin / blood
  • Islets of Langerhans / drug effects
  • Male
  • Pancreatic Hormones / blood*
  • Pancreatic Polypeptide / blood
  • Somatostatin / administration & dosage
  • Somatostatin / pharmacology*

Substances

  • Insulin
  • Pancreatic Hormones
  • Somatostatin
  • Pancreatic Polypeptide
  • Glucagon